Table 4 Summary of the cost-effectiveness of pegfilgrastim versus filgrastim in patients with lymphoma
Authors, y | Valuation year (currency measure used) | Incremental cost (US$2020) | Incremental effects | Original ICER | Adjusted ICER (US$2020per unit health outcome) | 1xGDP (US$ 2020) | Authors conclusion and recommendation |
|---|---|---|---|---|---|---|---|
Fust et al. 2017 [23] | 2014 (€) | US$ 1540 (6 days) US$ 452 (11 days) | 0.374 FN averted, 0.303 LYs gained and 0.268 QALY gained (6 days) 0.118 FN averted, 0.106 LYs, and 0.094 QALY (11 days) | US$ 3653 per QALY US$ 2617 per FN averted, US$ 3231 per LYs | US$ 5749 per QALY US$ 4120 per FN averted; US$ 5085 per LYs gained, US$ 3828 per FN averted US$ 4261 per LYs, US$ 4805 per QALY | 44,594 | Pegfilgrastim appears cost effective compared to other prophylaxis strategies |
Ravangard et al.2017 [33] | 2014 (US$) | US$ 378 and US$ 566 | 0.02 and 0.14 FN averted | US$ 17,000 per FN averted (dominant) and - US$ 3635.7 (dominant) | US$ 18,89 per FN averted and US$ 404 per FN averted | 2423 | Pegfilgrastim strategies were more cost effective |
Wang et al. 2016 [24] | 2013 (US$) | US$ 274 at cycle 1 and 2, US$ 887 at all cycles | 0.0001 QALY; 0.01 FN prevented (at cycle 1 and 2), 0.02 FN prevented (at all cycles) | US$ 4,058,623 QALY gained at all cycles and US$ 24,300 per FN prevented (cycle 1) US$ 39,300 per FN prevented (cycle 2) | US$ 8,871,600 per QALY gained, US$ 27,428 per FN averted, US$ 44,358 per FN averted | 59,798 | Pegfilgrastim is cost effective |
Lathia et al. 2013 [19] | 2012 (CAN$) | US$ 2228 | 0.0009 QALY | CAN$ 2,611,000 per QALY | US$ 2,475,344 per QALY gained | 43,258 | Dominated, pegfligrastim is not cost effective |
Perrier et al.2013 [32] | 2009 (€) | US$ 6410 | 0.22 FN avoided | Dominant | US$ 29,135 per FN averted | 38,625 | Pegfilgrastim dominate filgrastim |
Sebban et al.2012 [31] | 2009 (€) | US$ 3822 | 0.22 FN avoided | Dominant | US$ 17,372.95 per FN averted | 38,625 | Pegfilgrastim was cost-effective |
Whyte et al. 2011 [21] | 2010 (€) | US$ 345 (6 days), US$ 6397 (11 days) | 0.056 QALY | US$ 3625 per QALY and dominant | US$ 6159 per QALY US$ 14,229per QALY gained | 40,285 | Pegfilgrastim was the most cost-effective of G-CSF |
Lyman et al. 2009 [22] | 2006 (US$) | US$ 341 | Scenario 1 = 0.047 LYs, Scenario 2 = 0.042 QALY,0.174 LYs, Scenario 3 = 0.155 QALY | US$ 6190 per QALY, US$ 2167 per FN avoided, US$ 5532 per LYs | US$ 8114 per QALY US$ 2199 per QALY US$ 2840 per FN averted US$ 7251 per LYs | 63,544 | Pegfilgrastim is cost-effective compared to 6 days filgrastim |